Maria Julia Montoro

Maria Julia Montoro

Auto-generated profile, based on publicly available information

Maria Julia Montoro

Department of Hematology Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DFDavid Valcárcel Ferreiras
David Valcárcel Ferreiras
VAVera Ademà
Vera Ademà
FSFrancesc Solé
Francesc Solé
MOMargarita Ortega
Margarita Ortega
BNBenet Nomdedeu
Benet Nomdedeu
TVTeresa Vallespí
Teresa Vallespí
Purpose: Complex karyotype (CK) is the poorest risk factor in patients with myelodysplastic syndrome (MDS). It has recently been reported that monosomal karyotype (MK) worsens the prognosis of patients with CK.Patients and Methods: We analyzed 1,054 adult patients with MDS with an abnormal karyotype from the Spanish Registry of MDS. The aim of the study was to describe the incidence, characteristics, and prognosis of MK; the main end points were overall survival (OS) and leukemia-free survival.Results: MK was identified in 172 patients (16%), most of whom (88%) presented with CK. Variables significantly associated with OS were age (hazard ratio [HR], 1.90; P < .001), bone marrow (BM) blast percentage (HR, 1.05; P < .001), hemoglobin level (HR, 1.71; P < .001), platelet count (HR, 1.41; P < .001), karyotype complexity (CK [three abnormalities]: HR, 1.81; P = .003; very CK [> three abnormalities]: HR, 2; P < .001), and abnormalities of chromosome 5 and/or 7 (HR, 1.89; P < .001). Variables significantly related to the risk of transformation to acute myeloid leukemia (AML) were higher BM blast percentage (HR, 1.12; P < .001) and karyotype complexity (CK: HR, 2.53; P = .002; very CK: HR, 2.77; P < .001).Conclusion: After accounting for karyotype complexity, MK was not associated with OS or evolution to AML. In conclusion, these results demonstrate that the prognostic value of MK in MDS is not independent and is mainly the result of its strong association with number of chromosomal abnormalities.

17 October 2024 in Blood
Verified
Journal Article
Closed access
MMMaria Julia Montoro
Maria Julia Montoro
LPLaura Palomo
Laura Palomo
CHClaudia Haferlach
Claudia Haferlach
PAPamela Acha
Pamela Acha
OCOnyee Chan
Onyee Chan
DVDavid Valcárcel
David Valcárcel
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, whereas the remaining patients displayed monoallelic mutations. TP53-multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53-monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53-monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53-multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q).

1 June 2015 in The Lancet Haematology
Verified
Journal Article
Closed access
DFDavid Valcárcel Ferreiras
David Valcárcel Ferreiras
GSGuillermo Sanz
Guillermo Sanz
MOMargarita Ortega
Margarita Ortega
BNBenet Nomdedeu
Benet Nomdedeu
ELElisa Luño
Elisa Luño
TVTeresa Vallespí
Teresa Vallespí

12 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSílvia Saumell
Sílvia Saumell
FSFrancesc Solé
Francesc Solé
Leonor ArenillasLeonor Arenillas
Leonor Arenillas
JMJulia Montoro
Julia Montoro
DFDavid Valcárcel Ferreiras
David Valcárcel Ferreiras
LFLourdes Florensa
Lourdes Florensa
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy 8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulocytes, CD3+ lymphocytes and oral mucosa cells by fluorescence in situ hybridization (FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough evidence to MDS.

20 September 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Leonor ArenillasLeonor Arenillas
Leonor Arenillas
Xavier CalvoXavier Calvo
Xavier Calvo
ELElisa Luño
Elisa Luño
LSLeonor Senent
Leonor Senent
EAEsther Alonso
Esther Alonso
LFLourdes Florensa
Lourdes Florensa
PurposeWHO classification of myeloid malignancies is based mainly on the percentage of bone marrow (BM) blasts. This is considered from total nucleated cells (TNCs), unless there is erythroid-hyper...

1 December 2016 in Laboratory Investigation
Verified
Journal Article
Closed access
Xavier CalvoXavier Calvo
Xavier Calvo
Leonor ArenillasLeonor Arenillas
Leonor Arenillas
ELElisa Luño
Elisa Luño
LSLeonor Senent
Leonor Senent
MAMontserrat Arnan
Montserrat Arnan
LFLourdes Florensa
Lourdes Florensa